GO
Loading...

Teva Pharmaceutical Industries Ltd

More

  • March 2- U.S. generic drug maker Mylan Inc is still on the prowl for more deals, after completing the multibillion-dollar acquisition of some of Abbott Laboratories' non-U.S. businesses just last week. The company forecast 2015 revenue of $9.6 billion to $10.1 billion and adjusted earnings of $4 to $4.30 per share. The company said it still expects to launch a...

  • *Q4 adjusted EPS $1.31, in line with expectations. TEL AVIV, Feb 5- Teva Pharmaceutical Industries is ready to return to making acquisitions, it said on Thursday, after a year of focusing on costs under its new chief executive. The company posted fourth-quarter earnings of $1.31 per diluted share, excluding one-time items, against $1.42 a year earlier.

  • Teva Pharm Q4 profit, revenue meet expectations Thursday, 5 Feb 2015 | 7:38 AM ET

    TEL AVIV, Feb 5- Teva Pharmaceutical Industries reported quarterly profit that met analysts' estimates on Thursday and reaffirmed its earnings forecast for the full year. Teva, the world's largest generic drugmaker and Israel's biggest company, earned $1.31 per diluted share excluding one-time items in the fourth quarter, compared with $1.42 a year earlier.

  • Jan 26- The U.S. Food and Drug Administration said it approved Teva Pharmaceutical Industries Ltd's generic version of AstraZeneca Plc's blockbuster heartburn drug Nexium, the agency's first such approval for the drug. Nexium raked in about $1.9 billion in global sales in the first half of 2014, according to AstraZeneca's latest earnings statement.

  • WASHINGTON, Jan 26- The U.S. Supreme Court on Monday sent three patent cases, including one dispute over Shire Plc's Lialda drug, back to a lower court for further proceedings in light of a ruling the justices issued last week. Watson Pharmaceuticals, U.S. Supreme Court, No. 14-206.. Butamax Advanced Fuels LLC and Lighting Ballast Control LLC v.

  • WASHINGTON, Jan 20- The U.S. Supreme Court on Tuesday ruled that Teva Pharmaceutical Industries Ltd can still benefit from patent protection for top-selling multiple sclerosis drug Copaxone, dealing a blow to generic drugmakers looking to market a cheaper rival product. In a 7-2 vote, the justices sent the case back to the U.S. Court of Appeals for the Federal...

  • WASHINGTON, Jan 20- The U.S. Supreme Court on Tuesday ruled for Teva Pharmaceutical Industries Ltd in its fight with generic drug manufacturers over patent protections for Copaxone, its top-selling multiple sclerosis drug, by sending the case back to a lower court for further review. On a 7-2 vote, the justices said that the U.S. Court of Appeals for the Federal...

  • WASHINGTON, Jan 20- The U.S. Supreme Court on Tuesday ruled for Teva Pharmaceutical Industries Ltd in its fight with generic drug manufacturers over patent protections for Copaxone, its top-selling multiple sclerosis drug, by sending the case back to a lower court for further review.

  • Jan 5- Staff reviewers at the U.S. Food and Drug Administration recommended approval for Novartis AG's copy of Amgen Inc's blockbuster cancer drug Neupogen. Novartis's drug is the first to be reviewed in the United States under the so-called biosimilar pathway. The reviewers recommended that Novartis's copy should be approved for all the five indications...

  • TEL AVIV, Dec 11- Teva Pharmaceutical Industries forecast 2015 revenue below analysts' expectations, due to adverse foreign exchange moves and generic competition for its best-selling multiple sclerosis treatment Copaxone. There are two teams developing cheaper generic forms of Copaxone: one involving Novartis AG's Sandoz Inc and Momenta...

  • NEW YORK/ WINNIPEG, Dec 9- Valeant Pharmaceuticals International Inc is abandoning its growth-by-acquisitions strategy for the time being to try to reduce debt, boost its stock price and one day return to its traditional deal-making in a stronger position, people familiar with the matter told Reuters. Speculation about Valeant's next takeover target has...

  • NEW YORK/ WINNIPEG, Dec 9- Valeant Pharmaceuticals International Inc is abandoning its growth-by-acquisitions strategy for the time being to try to reduce debt, boost its stock price and one day return to its traditional deal-making in a stronger position, people familiar with the matter told Reuters. Speculation about Valeant's next takeover target has...

  • Dec 5- A Massachusetts jury has found that an agreement between AstraZeneca Plc and Ranbaxy Laboratories Ltd to delay the launch of a generic version of AstraZeneca's heartburn drug Nexium was not anticompetitive. AstraZeneca and an attorney for Ranbaxy released statements saying they were pleased with the verdict. The lawsuit, which began in 2012,...

  • Teva Pharma names Peterburg new chairman Wednesday, 26 Nov 2014 | 1:39 PM ET

    Nov 26- The board of Teva Pharmaceutical Industries Ltd elected Yitzhak Peterburg as its chairman, succeeding Phillip Frost, who is due to step down at the end of the year. The company also appointed Sol Barer, the former chief executive of Celgene Corp, as a director. Teva stock was up 0.8 percent at $57.02 on the New York Stock Exchange.

  • Your first trade for Tuesday Monday, 27 Oct 2014 | 6:33 PM ET

    The "Fast Money" traders share their final trades of the day.

  • WASHINGTON, Oct 15- The U.S. Supreme Court on Wednesday appeared closely divided as it weighed Teva Pharmaceutical Industries Ltd's high-profile fight with generic drug manufacturers over patent protections for Copaxone, its top-selling multiple sclerosis drug. Israel- based Teva is battling to protect a key patent for the $4- billion- a-year MS drug that is...

  • WASHINGTON, Oct 15- The U.S. Supreme Court on Wednesday appeared closely divided as it weighed Teva Pharmaceutical Industries Ltd's high-profile fight with generic drug manufacturers over patent protections for Copaxone, its top-selling multiple sclerosis drug. The $4- billion- a-year drug accounts for 50 percent of Teva profits, and the patent fight is one...

  • WASHINGTON, Oct 15- The U.S. Supreme Court on Wednesday is set to wade into Teva Pharmaceutical Industries Ltd's fight over patent protections for Copaxone, its top-selling multiple sclerosis drug, in one of the most important business cases of the justices' new term. There are two teams developing cheaper generic forms of Copaxone: one involving Novartis AG's...

  • Oct 8- Amgen Inc said its copycat version of AbbVie Inc's blockbuster biotech drug Humira showed comparable safety and ability to generate immune response in patients with a type of skin disease. "We remain bullish about AMGN's biosimilar prospects given the manufacturing expertise which would likely be key for success in biosimilar competition," Deutsche...

  • WASHINGTON, Oct 3- Gay marriage may be the most anticipated issue heading for the U.S. Supreme Court, but the justices also must tackle a host of business cases as they convene for their new term, including a patent battle involving Teva Pharmaceutical Industries Ltd.. The case also has broader ramifications in the patent arena as shown by the number of businesses...